» Articles » PMID: 23900071

Pathological Mechanisms Underlying TDP-43 Driven Neurodegeneration in FTLD-ALS Spectrum Disorders

Overview
Journal Hum Mol Genet
Date 2013 Aug 1
PMID 23900071
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Aggregation of misfolded TAR DNA-binding protein 43 (TDP-43) is a striking hallmark of neurodegenerative processes that are observed in several neurological disorders, and in particular in most patients diagnosed with frontotemporal lobar degeneration (FTLD) or amyotrophic lateral sclerosis (ALS). A direct causal link with TDP-43 brain proteinopathy was provided by the identification of pathogenic mutations in TARDBP, the gene encoding TDP-43, in ALS families. However, TDP-43 proteinopathy has also been observed in carriers of mutations in several other genes associated with both ALS and FTLD demonstrating a key role for TDP-43 in neurodegeneration. To date, and despite substantial research into the biology of TDP-43, its functioning in normal brain and in neurodegeneration processes remains largely elusive. Nonetheless, breakthroughs using cellular and animal models have provided valuable insights into ALS and FTLD pathogenesis. Accumulating evidence has redirected the research focus towards a major role for impaired RNA metabolism and protein homeostasis. At the same time, the concept that toxic TDP-43 protein aggregates promote neurodegeneration is losing its credibility. This review aims at highlighting and discussing the current knowledge on TDP-43 driven pathomechanisms leading to neurodegeneration as observed in TDP-43 proteinopathies. Based on the complexity of the associated neurological diseases, a clear understanding of the essential pathological modifications will be crucial for further therapeutic interventions.

Citing Articles

The Regulation of TDP-43 Structure and Phase Transitions: A Review.

Liu Y, Xiang J, Gong H, Yu T, Gao M, Huang Y Protein J. 2025; .

PMID: 39987392 DOI: 10.1007/s10930-025-10261-0.


Heterogeneous Nuclear Ribonucleoprotein A1 Knockdown Alters Constituents of Nucleocytoplasmic Transport.

Stang T, Salapa H, Clarke J, Popescu B, Levin M Brain Sci. 2024; 14(10).

PMID: 39452051 PMC: 11505608. DOI: 10.3390/brainsci14101039.


TDP-43 dysfunction leads to bioenergetic failure and lipid metabolic rewiring in human cells.

Ceron-Codorniu M, Torres P, Fernandez-Bernal A, Rico-Rios S, Serrano J, Miralles M Redox Biol. 2024; 75:103301.

PMID: 39116527 PMC: 11362800. DOI: 10.1016/j.redox.2024.103301.


Pathologic TDP-43 downregulates myelin gene expression in the monkey brain.

Zhu L, Bai D, Wang X, Ou K, Li B, Jia Q Brain Pathol. 2024; 34(6):e13277.

PMID: 38779803 PMC: 11483520. DOI: 10.1111/bpa.13277.


Nuclear and degradative functions of the ESCRT-III pathway: implications for neurodegenerative disease.

Keeley O, Coyne A Nucleus. 2024; 15(1):2349085.

PMID: 38700207 PMC: 11073439. DOI: 10.1080/19491034.2024.2349085.


References
1.
Elden A, Kim H, Hart M, Chen-Plotkin A, Johnson B, Fang X . Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010; 466(7310):1069-75. PMC: 2965417. DOI: 10.1038/nature09320. View

2.
Ishiura H, Takahashi Y, Mitsui J, Yoshida S, Kihira T, Kokubo Y . C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Arch Neurol. 2012; 69(9):1154-8. DOI: 10.1001/archneurol.2012.1219. View

3.
Greenway M, Andersen P, Russ C, Ennis S, Cashman S, Donaghy C . ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet. 2006; 38(4):411-3. DOI: 10.1038/ng1742. View

4.
Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong M . Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2008; 1249:202-11. DOI: 10.1016/j.brainres.2008.10.021. View

5.
Johnson B, McCaffery J, Lindquist S, Gitler A . A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2008; 105(17):6439-44. PMC: 2359814. DOI: 10.1073/pnas.0802082105. View